Balyasny Asset Management
KALV

Balyasny Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Balyasny Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,098
Closed -$223K – 3264
2026
Q1 		$223K Buy
+11,098
New +$179K ﹤0.01% 2659
2024
Q4 		– Sell
-26,968
Closed -$312K – 3009
2024
Q3 		$312K Buy
+26,968
New +$339K ﹤0.01% 2443
2024
Q1 		– Sell
-11,905
Closed -$146K – 2874
2023
Q4 		$146K Buy
11,905
+1,235
+12% +$11.2K ﹤0.01% 2352
2023
Q3 		$103K Buy
+10,670
New +$109K ﹤0.01% 2126

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's KALV Position: Q2 2026 in Review

Balyasny Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 11,098 shares — an estimated $223K sold.

Balyasny Asset Management first reported a position in KALV in Q3 2023 and held it in 4 quarters. The position peaked at $312K in Q3 2024. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Balyasny Asset Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 11,098 KalVista Pharmaceuticals shares in Q2 2026, an estimated $223K.
  • Balyasny Asset Management first reported a position in KalVista Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Balyasny Asset Management's KalVista Pharmaceuticals position peaked at $312K in Q3 2024.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.